MEDISUPPLY: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
MEDISUPPLY
Largest movements
- Stocks and contracts +€11,814
up €11,814 (+239%), from €4,946 to €16,760
- Cash +€9,986
up €9,986 (+320%), from €3,125 to €13,111
mainly Other debts (+€29,076) and Trade debts (+€298)
- Receivables within one year +€6,300
up €6,300 (+1,685%), from €374 to €6,674
of which Trade receivables: +€5,492
- Other debts +€29,076
new in 2025: €29,076
- Profit (loss) carried forward -€1,274
down €1,274 (-31.4%), from -€4,056 to -€5,330
- Gross operating margin +€6,492
up €6,492, from -€3,640 to €2,853
- Other operating charges +€2,449
up €2,449 (+632%), from €387 to €2,836
- Financial charges +€1,262
up €1,262 (+4,427%), from €29 to €1,290
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €8,444 | €36,544 | +€28,100 | +333% |
| Current assets | 29/58 | €8,444 | €36,544 | +€28,100 | +333% |
| Stocks and contracts in progress | 3 | €4,946 | €16,760 | +€11,814 | +239% |
| Stocks | 30/36 | €4,946 | €16,760 | +€11,814 | +239% |
| Amounts receivable within one year | 40/41 | €374 | €6,674 | +€6,300 | +1,685% |
| Trade receivables | 40 | €175 | €5,667 | +€5,492 | +3,139% |
| Other amounts receivable | 41 | €199 | €1,006 | +€807 | +406% |
| Cash at bank and in hand | 54/58 | €3,125 | €13,111 | +€9,986 | +320% |
| Total equity and liabilities | 10/49 | €8,444 | €36,544 | +€28,100 | +333% |
| Equity | 10/15 | €7,944 | €6,670 | -€1,274 | -16.0% |
| Contributions | 10/11 | €12,000 | €12,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€4,056 | -€5,330 | -€1,274 | -31.4% |
| Amounts payable | 17/49 | €500 | €29,874 | +€29,374 | +5,875% |
| Amounts payable within one year | 42/48 | - | €29,374 | +€29,374 | |
| Trade debts | 44 | - | €298 | +€298 | |
| Suppliers | 440/4 | - | €298 | +€298 | |
| Other amounts payable | 47/48 | - | €29,076 | +€29,076 | |
| Accrued charges and deferred income | 492/3 | €500 | €500 | = | 0.0% |
| Other operating charges | 640/8 | €387 | €2,836 | +€2,449 | +632% |
| Gross operating margin | 9900 | -€3,640 | €2,853 | +€6,492 | |
| Operating profit (loss) | 9901 | -€4,027 | €16 | +€4,043 | |
| Financial charges | 65/66B | €29 | €1,290 | +€1,262 | +4,427% |
| Recurring financial charges | 65 | €29 | €1,290 | +€1,262 | +4,427% |
| Profit (loss) for the period before taxes | 9903 | -€4,056 | -€1,274 | +€2,782 | +68.6% |
| Profit (loss) for the period | 9904 | -€4,056 | -€1,274 | +€2,782 | +68.6% |
| Profit (loss) for the period to be appropriated | 9905 | -€4,056 | -€1,274 | +€2,782 | +68.6% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 20 October 2026 via checked.be.